Abstract |
The literature suggests that variations in anticoagulant effect occur when acenocoumarol is administrated in a daily dose. We assessed the anticoagulant effects of acenocoumarol with INR, factors VII and X and protein C in 12 randomly selected hospitalised patients with deep-vein thrombosis, six of them receiving a daily dose of acenocoumarol, the other six receiving twice daily doses. When the drug effect had been at a steady-state for at least 72 h, five blood samples were drawn per patient over a period of 24 h. No nycthemeral significant variations were noted for INR, factor X and protein C in the two groups (P > 0.10). Nycthemeral significant variation in factor VII when acenocoumarol was administered once daily was noted (P = 0.02), but the clinical relevance of factor VII variation at steady-state is uncertain. In spite of the short pharmacokinetic half-life of acenocoumarol, a stable nycthemeral pharmacodynamic activity was observed after once daily administration; twice-daily administration of acenocoumarol does not appear to be justified.
|
Authors | P Mismetti, J Reynaud, S Laporte-Simitsidis, H Thijssen, B Tardy-Poncet, B Tardy, A Buchmuller, H Decousus |
Journal | Fundamental & clinical pharmacology
(Fundam Clin Pharmacol)
Vol. 12
Issue 6
Pg. 631-5
( 1998)
ISSN: 0767-3981 [Print] England |
PMID | 9818296
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Acenocoumarol
|
Topics |
- Acenocoumarol
(administration & dosage, pharmacokinetics, pharmacology)
- Administration, Oral
- Aged
- Anticoagulants
(administration & dosage, pharmacokinetics, pharmacology)
- Female
- Humans
- Male
- Middle Aged
- Time Factors
- Venous Thrombosis
(drug therapy, metabolism)
|